Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Target Price at $23.80

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has been given an average rating of “Buy” by the six research firms that are covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $23.80.

A number of equities research analysts recently commented on LXEO shares. Chardan Capital increased their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Leerink Partners decreased their target price on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Finally, HC Wainwright raised their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th.

Lexeo Therapeutics Trading Down 2.3 %

NASDAQ:LXEO opened at $5.07 on Friday. Lexeo Therapeutics has a 52 week low of $4.78 and a 52 week high of $22.33. The firm has a 50 day moving average of $6.87 and a 200 day moving average of $9.48. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $167.66 million, a price-to-earnings ratio of -1.60 and a beta of 3.08.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LXEO. Frazier Life Sciences Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the third quarter worth $11,307,000. Janus Henderson Group PLC increased its stake in shares of Lexeo Therapeutics by 18.9% in the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after acquiring an additional 599,203 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the third quarter worth $3,348,000. Verition Fund Management LLC increased its stake in shares of Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after acquiring an additional 355,928 shares during the period. Finally, Ikarian Capital LLC acquired a new stake in shares of Lexeo Therapeutics in the third quarter worth $2,325,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.